NCT04640987View on ClinicalTrials.gov

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2029

Conditions
Hematologic Diseases
Interventions
BIOLOGICAL

Allogeneic Stem Cell Transplant

The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.

DEVICE

CliniMACS Prodigy System

Device used for production of T-allo10 cells.

DRUG

T-allo10 cells addback

T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.

Trial Locations (1)

94305

RECRUITING

Lucile Packard Children's Hospital, Palo Alto

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Porteus, Matthew, MD

OTHER